Subunit-specific mass spectrometry method identifies haptoglobin subunit alpha as a diagnostic marker in non-small cell lung cancer

Journal of Proteomics

Volumn 94, Issue , 2013, Pages 302-310

  Park, Jisook ^a   Yang, Jeong Soo ^a   Jung, Gyuyon ^a   Woo, Hye In ^b   Park, Hyung Doo ^b   Kim, Jong Won ^b   Huh, Wooseong ^a,b   Ko, Jae Wook ^a   Kim, Hojoong ^b   Cho, Je Yoel ^c   Lee, Soo Youn ^a,b  

^a Samsung Medical Center   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Biomarker; Haptoglobin; Lung cancer; Mass spectrometry; Multiple reaction monitoring

Indexed keywords

HAPTOGLOBIN; HAPTOGLOBIN SUBUNIT ALPHA; HAPTOGLOBIN SUBUNIT BETA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ALPHA CHAIN; ARTICLE; BETA CHAIN; CANCER DIAGNOSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN DEGRADATION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; STABLE ISOTOPE DILUTION MULTIPLE REACTION MONITORING MASS SPECTROMETRY;

AC; ADENOCARCINOMA; AREA UNDER THE ROC CURVE; AUC; BIOMARKER; CARCINOEMBRYONIC ANTIGEN; CEA; CYFRA 21-1; CYTOKERATIN FRAGMENT 19; DECLUSTERING POTENTIAL; DP; ELISA; ENHANCED PRODUCT ION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPI; HAPTOGLOBIN; HP; INTERNAL STANDARD; IS; LUNG CANCER; MASS SPECTROMETRY; MULTIPLE REACTION MONITORING; NEURON SPECIFIC ENOLASE; NON-SMALL CELL LUNG CANCER; NSCLC; NSE; POST-TRANSLATIONAL MODIFICATION; PRO-GASTRIN-RELEASING PEPTIDE; PROGRP; PTM; RECEIVER OPERATING CHARACTERISTIC; ROC; SCC; SCLC; SID-MRM-MS; SMALL CELL LUNG CANCER; SQUAMOUS CELL CARCINOMA; STABLE ISOTOPE DILUTION-MULTIPLE REACTION MONITORING MASS SPECTROMETRY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; HAPTOGLOBINS; HUMANS; LUNG NEOPLASMS; MALE; MASS SPECTROMETRY; MIDDLE AGED; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84886606816     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.09.019     Document Type: Article

References (29)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
2. Jung K.W., Park S., Kong H.J., Won Y.J., Lee J.Y., Park E.C., et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat 2011, 43:1-11.
3. Molina R., Filella X., Auge J.M., Fuentes R., Bover I., Rifa J., et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 2003, 24:209-218.
4. Zeng X., Hood B.L., Zhao T., Conrads T.P., Sun M., Gopalakrishnan V., et al. Lung cancer serum biomarker discovery using label-free liquid chromatography-tandem mass spectrometry. J Thorac Oncol 2011, 6:725-734.
5. Du J., Yang S.Y., Lin X.L., Shang W.L., Zhang W., Huo S.F., et al. Biomarker discovery and identification from non-small cell lung cancer sera. Front Biosci (Elite Ed) 2011, 3:1-10.
6. Zeng X., Hood B.L., Sun M., Conrads T.P., Day R.S., Weissfeld J.L., et al. Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry. J Proteome Res 2010, 9:6440-6449.
7. Au J.S., Cho W.C., Yip T.T., Law S.C. Proteomic approach to biomarker discovery in cancer tissue from lung adenocarcinoma among nonsmoking Chinese women in Hong Kong. Cancer Invest 2008, 26:128-135.
8. Bharti A., Ma P.C., Salgia R. Biomarker discovery in lung cancer-promises and challenges of clinical proteomics. Mass Spectrom Rev 2007, 26:451-466.
9. Valle R.P., Chavany C., Zhukov T.A., Jendoubi M. New approaches for biomarker discovery in lung cancer. Expert Rev Mol Diagn 2003, 3:55-67.
10. Asleh R., Marsh S., Shilkrut M., Binah O., Guetta J., Lejbkowicz F., et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res 2003, 92:1193-1200.
11. Quaye I.K. Haptoglobin, inflammation and disease. Trans R Soc Trop Med Hyg 2008, 102:735-742.
12. Sadrzadeh S.M., Bozorgmehr J. Haptoglobin phenotypes in health and disorders. Am J Clin Pathol 2004, 121:S97-S104. [Suppl.].
13. Delanghe J.R., Langlois M.R., Boelaert J.R., Van Acker J., Van Wanzeele F., van der Groen G., et al. Haptoglobin polymorphism, iron metabolism and mortality in HIV infection. AIDS 1998, 12:1027-1032.
14. Delanghe J., Langlois M., Duprez D., De Buyzere M., Clement D. Haptoglobin polymorphism and peripheral arterial occlusive disease. Atherosclerosis 1999, 145:287-292.
15. Shah A., Singh H., Sachdev V., Lee J., Yotsukura S., Salgia R., et al. Differential serum level of specific haptoglobin isoforms in small cell lung cancer. Curr Proteomics 2010, 7:49-65.
16. Bharti A., Ma P.C., Maulik G., Singh R., Khan E., Skarin A.T., et al. Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res 2004, 24:1031-1038.
17. Bronstrup M. Absolute quantification strategies in proteomics based on mass spectrometry. Expert Rev Proteomics 2004, 1:503-512.
18. Kirkpatrick D.S., Gerber S.A., Gygi S.P. The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications. Methods 2005, 35:265-273.
19. Gerber S.A., Rush J., Stemman O., Kirschner M.W., Gygi S.P. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci U S A 2003, 100:6940-6945.
20. Barr J.R., Maggio V.L., Patterson D.G., Cooper G.R., Henderson L.O., Turner W.E., et al. Isotope dilution-mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I. Clin Chem 1996, 42:1676-1682.
21. Tabassum U., Reddy O., Mukherjee G. Elevated serum haptoglobin is associated with clinical outcome in triple-negative breast cancer patients. Asian Pac J Cancer Prev 2012, 13:4541-4544.
22. Kim Y.W., Bae S.M., Kim I.W., Liu H.B., Bang H.J., Chaturvedi P.K., et al. Multiplexed bead-based immunoassay of four serum biomarkers for diagnosis of ovarian cancer. Oncol Rep 2012, 28:585-591.
23. Park S.Y., Lee S.H., Kawasaki N., Itoh S., Kang K., Hee Ryu S., et al. Alpha1-3/4 fucosylation at Asn 241 of beta-haptoglobin is a novel marker for colon cancer: a combinatorial approach for development of glycan biomarkers. Int J Cancer 2012, 130:2366-2376.
24. Yee J., Sadar M.D., Sin D.D., Kuzyk M., Xing L., Kondra J., et al. Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. J Clin Oncol 2009, 27:2787-2792.
25. Ulivi P., Mercatali L., Casoni G.L., Scarpi E., Bucchi L., Silvestrini R., et al. Multiple marker detection in peripheral blood for NSCLC diagnosis. PLoS One 2013, 8:e57401.
26. Shu H., Kang X., Guo K., Li S., Li M., Sun L., et al. Diagnostic value of serum haptoglobin protein as hepatocellular carcinoma candidate marker complementary to alpha fetoprotein. Oncol Rep 2010, 24:1271-1276.
27. Yang Y., Zhao S., Fan Y., Zhao F., Liu Q., Hu W., et al. Detection and identification of potential biomarkers of non-small cell lung cancer. Technol Cancer Res Treat 2009, 8:455-466.
28. Kang S.M., Sung H.J., Ahn J.M., Park J.Y., Lee S.Y., Park C.S., et al. The Haptoglobin beta chain as a supportive biomarker for human lung cancers. Mol Biosyst 2011, 7:1167-1175.
29. Ye B., Cramer D.W., Skates S.J., Gygi S.P., Pratomo V., Fu L., et al. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 2003, 9:2904-2911.